Genedrift

Myanmar

Myanmar’s percapita pharma expenditure in 2017 was 8.5 and is expected to reach $1.1b by 2023. Myanmar’s economy is growing continuously, and the pharmaceutical industry is predicted to grow at the same pace if not faster, as compared to other peers.

Why is the market growing?

Rising incomes as a results of liberalization and entry of foreign companies 

A large increase in the number of hospitals across the country with majority of these being funded by the government

Great demand, larger penetration and increased access down the lower income groups 


Increasing healthcare spending by the government and larger literacy rates coupled with influx of large foreign conglomerates

Disease trends in Myanmar

Globally, cardiovascular diseases, chronic respiratory diseases, cancers, and diabetes are the four major non-communicable diseases (NCDs) contributing to more than 80% of mortality and morbidity due to NCDs. 

In Myanmar, the proportional mortality rate due to NCDs increased from 46.9% in 2000 to 68% in 2017.

AIDS, tuberculosis and malaria were the top priority issues of National Health Plan for the years 2006 to 2011. The number of persons infected with HIV/AIDS was estimated to be 330 thousand with a prevalence rate of 1.3 percent. Malaria and tuberculosis were two leading causes of death.

Preferential Treatment

The country's majority healthcare spending is through personal sourcse. Insurance and government spending on healthcare still lags and does not cover majority of the population. 

The regulatory system treats all manufacturers, irrespective of country of origin - as same and offers no partiality based on the source or site of manufacturer. 


The local population has a very high acceptance for products manufacturers within SEA along with those manufactured across Australia and EU

Road ahead !

Local manufacturing meets less than 7-10% of the total demand, and has almost negligible investment on R&D.
Most local manufacturers are government owned and produce medium-low quality generic drugs targeting majorly government procurement.


The country does not permit unregistered products, has limited regulatory restrictions and is open to quality products and innovative therapies. 
Although major efforts were made to bring in foreign manufacturers, but not much progress has been attained so far, with majority of companies exporting to Myanmar.

Looking for more regulatory information, please visit the Resources Section.


Decided to move forward with Registration of your products, get in touch with us 

Get Started Now

Privacy Policy

Genedrift LLC ©